Selection of a novel anti-nicotine vaccine: influence of antigen design on antibody function in mice
about
Biologic Approaches to Treat Substance-Use DisordersNovel Anti-Nicotine Vaccine Using a Trimeric Coiled-Coil Hapten CarrierConstruction of an enantiopure bivalent nicotine vaccine using synthetic peptides.The Effect of Physicochemical Modification on the Function of Antibodies Induced by Anti-Nicotine Vaccine in Mice.Characterization and optimization of heroin hapten-BSA conjugates: method development for the synthesis of reproducible hapten-based vaccines.Effect of currently approved carriers and adjuvants on the pre-clinical efficacy of a conjugate vaccine against oxycodone in mice and rats.Efficacy, but not antibody titer or affinity, of a heroin hapten conjugate vaccine correlates with increasing hapten densities on tetanus toxoid, but not on CRM197 carriersSynthesis of Hapten-Protein Conjugate Vaccines with Reproducible Hapten Densities.The frequency of early-activated hapten-specific B cell subsets predicts the efficacy of vaccines for nicotine dependence.A simple nonradioactive method for the determination of the binding affinities of antibodies induced by hapten bioconjugates for drugs of abuseInvestigating hapten clustering as a strategy to enhance vaccines against drugs of abuseRecent advances in the molecular design of synthetic vaccines.Prescreening of Nicotine Hapten Linkers in Vitro To Select Hapten-Conjugate Vaccine Candidates for Pharmacokinetic Evaluation in Vivo.Modern advances in heterocyclic chemistry in drug discovery.Conjugate Vaccine Immunotherapy for Substance Use Disorder.Hapten-specific naïve B cells are biomarkers of vaccine efficacy against drugs of abuse.A simple physiologically based pharmacokinetic model evaluating the effect of anti-nicotine antibodies on nicotine disposition in the brains of rats and humans.Biologics to treat substance use disorders: Current status and new directionsThe effect of preexisting anti-carrier immunity on subsequent responses to CRM197 or Qb-VLP conjugate vaccines.Current status and future prospects for the development of substance abuse vaccines.Engineering of a hybrid nanoparticle-based nicotine nanovaccine as a next-generation immunotherapeutic strategy against nicotine addiction: A focus on hapten density.Rationalization of a nanoparticle-based nicotine nanovaccine as an effective next-generation nicotine vaccine: A focus on hapten localization.Development of a Clinically Viable Heroin Vaccine.
P2860
Q28085073-498B6601-A63A-4DB2-A76D-60278C30230AQ28542642-6D892C1A-9596-4463-AA79-1F9AF2B5F629Q33751968-D00237D4-101A-40C2-99F0-2082DCD3830CQ33855905-C383AD87-146F-4C70-870C-EFED59499F4DQ34144813-48225621-4627-4BE1-8253-16860FB8D8A3Q35163178-7437EBBB-7DD8-4164-B51E-C651ECCE8789Q35756201-19B28DF3-0E07-4333-90F6-6DDA2E3632DBQ35989208-1D2DCBA6-B15F-44F6-AE00-E1B019C85661Q36278801-EADC14FA-FFEA-4184-8C65-3A583489D212Q36480112-E90657D5-F310-4C0D-BA54-9A22A4A6737EQ37697064-22E1A2B1-58AE-4A01-AE10-8E37DDA6D5E0Q38639938-ECD87B59-B8D7-47D9-85F6-6AEDFAC5A776Q38850703-4601DF2F-64E4-4C5C-ADCF-61BEAE861ECBQ38860432-3CF5E7CC-3AFA-4F02-964E-47CC39DAEA5EQ39387013-02E0421C-53BA-4D58-8693-04775AFD2F11Q39519649-F71BE634-4440-464C-A957-0DCBE7571A30Q39544975-8CD09757-5F14-48B7-925E-466FFA500C37Q39576940-703E7483-7D14-4020-883F-DC271A0A5503Q39816694-F2B1EDE3-7E40-4953-B184-1FCDBF2F7814Q43076031-6829D23B-8B5A-4B54-B16E-E313CE678853Q45052268-1FEE3A1C-7D60-4D68-9F15-915518A59F98Q45060078-D4E6FDC6-61D1-42F4-A409-46039D53F4BAQ45060547-279454C9-B82C-491C-BB80-308E656C852B
P2860
Selection of a novel anti-nicotine vaccine: influence of antigen design on antibody function in mice
description
2013 nî lūn-bûn
@nan
2013 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2013 թվականի հոտեմբերին հրատարակված գիտական հոդված
@hy
2013年の論文
@ja
2013年論文
@yue
2013年論文
@zh-hant
2013年論文
@zh-hk
2013年論文
@zh-mo
2013年論文
@zh-tw
2013年论文
@wuu
name
Selection of a novel anti-nico ...... n on antibody function in mice
@ast
Selection of a novel anti-nico ...... n on antibody function in mice
@en
type
label
Selection of a novel anti-nico ...... n on antibody function in mice
@ast
Selection of a novel anti-nico ...... n on antibody function in mice
@en
prefLabel
Selection of a novel anti-nico ...... n on antibody function in mice
@ast
Selection of a novel anti-nico ...... n on antibody function in mice
@en
P2093
P2860
P50
P1433
P1476
Selection of a novel anti-nico ...... n on antibody function in mice
@en
P2093
Alan D Brown
David C Blakemore
David C Pryde
David R Stead
Heather L Davis
James R Merson
Jotham W Coe
Karen Robertson
Matthew Badland
Matthew D Selby
P2860
P304
P356
10.1371/JOURNAL.PONE.0076557
P407
P577
2013-10-01T00:00:00Z